In a first-in-human study of MCARH109, an autologous GPRC5D-targeted CAR T-cell therapy, 17 patients with heavily pretreated MM were treated with a 71% response rate [20]. The gene discussed is GPRC5D; the disease is Miyoshi myopathy.